Roche’s Astegolimab Shows Mixed COPD Trial Results with Phase 2b Success, Phase 3 Failure; Columvi Faces U.S. Data Challenges

Roche's experimental drug astegolimab, developed for chronic obstructive pulmonary disease (COPD), has shown mixed results in clinical trials. The Phase 2b ALIENTO study met its primary endpoint by demonstrating a statistically significant reduction in the annualized exacerbation rate. However, the Phase 3 ARNASA study failed to meet its primary endpoint, which has delayed Roche's plans to seek regulatory approval this year. Additionally, astegolimab did not show improvements in clinical outcomes for patients hospitalized with COVID-19 pneumonia. Separately, Roche is facing challenges in advancing its earlier-stage lymphoma treatment, Columvi, due to a lack of U.S. data. These developments represent setbacks for Roche as it aims to accelerate the development of new treatments for serious lung conditions and cancers.